Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are monoclonal antibodies that block inhibitory receptors and ligands — chiefly CTLA-4 and the PD-1/PD-L1 axis — which tumours exploit to switch off antitumour T cells. By releasing these immune 'brakes', the drugs restore or amplify the patient's own T-cell-mediated response against the cancer, a strategy distinct from directly targeting the tumour cell.

Definition

Immune checkpoint inhibitors are antibodies that block inhibitory immune-regulatory pathways (such as CTLA-4 and PD-1/PD-L1), removing the negative signals that restrain T cells and thereby enabling or restoring T-cell-mediated antitumour immunity.

Scope

This topic covers the immune checkpoints that normally limit T-cell activity, how tumours co-opt them to evade immunity, the mechanism by which blocking antibodies restore antitumour responses, the role of biomarkers in predicting benefit, and the concept of immune-related adverse effects. It is reference-educational and contains no dosing or individualised treatment advice.

Core questions

• What are immune checkpoints, and why do they normally restrain T-cell activity?
• How do tumours exploit the CTLA-4 and PD-1/PD-L1 pathways to evade immune attack?
• How does blocking these pathways restore antitumour immunity?
• Which biomarkers help predict who will benefit, and why do immune-related adverse effects occur?

Key concepts

• Immune checkpoint (inhibitory receptor)
• CTLA-4 pathway
• PD-1/PD-L1 axis
• Tumour immune evasion
• T-cell exhaustion and reactivation
• Immune-related adverse events
• Predictive biomarkers (PD-L1 expression, tumour mutational burden)
• Durable response

Key theories

Checkpoint blockade releases antitumour immunity

Inhibitory checkpoints normally prevent excessive or self-directed T-cell activation; tumours engage these pathways to escape immune destruction, and antibody blockade of CTLA-4 or PD-1/PD-L1 lifts the restraint, allowing T cells to attack the tumour, as first shown clinically with anti-CTLA-4 in melanoma.

Mechanisms

T-cell activation is regulated by co-stimulatory and co-inhibitory signals. CTLA-4, expressed on activated T cells, competes with the co-stimulatory receptor CD28 for B7 ligands and dampens early T-cell activation in lymphoid tissue. PD-1, also induced on activated T cells, engages its ligands PD-L1 and PD-L2 in peripheral tissues and the tumour microenvironment, delivering an inhibitory signal that blunts effector function. Tumours exploit these pathways — for example by overexpressing PD-L1 — to inactivate infiltrating T cells. Blocking antibodies against CTLA-4 or against PD-1/PD-L1 interrupt these inhibitory signals, restoring T-cell proliferation, cytokine production, and cytotoxicity directed at the tumour. Because the same checkpoints maintain self-tolerance, their blockade can provoke immune-related inflammation of normal tissues. Biomarkers such as PD-L1 expression and tumour mutational burden are studied to predict which tumours are most likely to respond.

Clinical relevance

Checkpoint inhibitors have changed the treatment landscape for several cancers and are a leading example of harnessing the immune system rather than targeting the tumour cell directly. This entry explains the immunological mechanism to support understanding of how the class is categorised and acts; it is reference-educational and not a basis for individual diagnostic or treatment decisions.

Evidence & guidelines

The clinical foundation was established when ipilimumab, an anti-CTLA-4 antibody, improved overall survival in metastatic melanoma — the first therapy to do so in a randomised setting for that disease. Early-phase work with anti-PD-1 antibodies then demonstrated durable responses across several tumour types, and mechanistic reviews developed the biomarker framework used to guide checkpoint blockade.

History

Discovery in the 1990s that CTLA-4 and PD-1 act as inhibitory brakes on T cells, and that blocking them could unleash antitumour immunity, set the stage for the class. The 2010 demonstration that ipilimumab improved survival in metastatic melanoma provided the first clinical validation, and subsequent anti-PD-1 studies extended durable benefit to additional cancers. The underlying immunology was recognised with the 2018 Nobel Prize in Physiology or Medicine to James Allison and Tasuku Honjo.

Debates

Which biomarkers reliably predict benefit from checkpoint blockade?

PD-L1 expression, tumour mutational burden, and features of the immune microenvironment each carry predictive information, but none is universally reliable across tumour types, and identifying robust biomarkers remains an active question.

Key figures

• James Allison
• Tasuku Honjo
• Suzanne Topalian
• Drew Pardoll
• F. Stephen Hodi

Seminal works

• hodi-2010
• topalian-2012
• topalian-2016

Frequently asked questions

What is an immune checkpoint?

An immune checkpoint is an inhibitory receptor pathway — such as CTLA-4 or PD-1 — that normally limits T-cell activity to prevent excessive or self-directed immune responses; tumours can exploit these pathways to evade immune attack.

How do checkpoint inhibitors differ from drugs that target the tumour cell directly?

Rather than acting on the tumour cell, checkpoint inhibitors block the inhibitory signals that suppress the patient's T cells, restoring an immune response that then attacks the tumour.